Our purpose is to improve outcomes by developing therapies for serious, unmet medical conditions in the critical care setting where no, or limited, therapies are available.

About Us

Established in 2003, Atox Bio is a late stage biotechnology company that develops novel immunomodulators for critically ill patients. Our focus is on acute, life threatening, conditions resulting from a severe acute inflammation caused by severe infections.

Read More…

Technology

Short peptide immunomodulators capable of attenuating, but not inhibiting, excessive severe acute inflammation, commonly the cause of pathology and organ failure in severe infectious diseases. The peptides bind to a unique domain on CD28, a co-stimulatory receptor, affecting downstream.

Read More…

Pipeline

Pipeline

AB103 is being studied in ACCUTE, a phase 3 clinical trial in patients with Necrotizing Soft Tissue Infections. A phase 2 study is planned in patients with AKI. Additional indications are currently in pre-clinical studies.

…Read More